Updated on:
This article has been updated to reflect the December 28, 2024, CMS Final Rule establishing new personnel qualification requirements under Subpart M of 42 CFR Part 493; the January 1, 2025, implementation of the CMS-3355-F proficiency testing overhaul adding 29 new regulated analytes; and CMS’s transition to a fully paperless CLIA certification system.
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) establish the federal regulatory floor for every laboratory testing human specimens in the United States, outside clinical trials and basic research. Administered by the Centers for Medicare and Medicaid Services (CMS), the program sets mandatory standards for certification, test complexity categorization, quality control, proficiency testing, and personnel qualifications. Two recent regulatory actions, a personnel final rule and a proficiency testing overhaul, mean that laboratories operating on pre-2024 compliance assumptions are out of date.
Key Takeaways
- CLIA certification is mandatory for any U.S. facility testing human specimens for diagnosis, prevention, or treatment of disease, governed under 42 CFR Part 493.
- The FDA assigns each test a complexity category, waived, moderate, or high, which determines the certificate type, personnel requirements, and inspection schedule a lab must meet.
- CMS enacted the first major revision to CLIA personnel qualifications since 1992, updating degree requirements, introducing new roles, and codifying degree equivalency pathways.
- The CMS-3355-F proficiency testing final rule added 29 new regulated analytes and tightened grading criteria, requiring many labs to expand PT enrollment and revisit quality control thresholds.
- More than 317,000 CLIA-certified facilities operate under the program; roughly 80% hold a Certificate of Waiver, while the remainder perform nonwaived testing subject to biennial inspections.
CLIA Certification: Five Certificate Types and What Each Requires
CLIA does not issue a single credential. A laboratory must hold the certificate matching the highest complexity level of testing it performs.
A Certificate of Waiver (CoW) authorizes only FDA-waived tests, such as dipstick urinalysis, blood glucose monitoring, urine pregnancy tests, and rapid antigen assays. CoW holders follow manufacturer instructions but face no routine inspection. As of March 2024, roughly 244,791 U.S. laboratories hold this certificate, representing approximately 80% of all non-exempt CLIA-certified facilities.
A Certificate for Provider-Performed Microscopy (PPM) covers a narrow set of moderate-complexity microscopy examinations performed during patient office visits. PPM holders are exempt from routine quality systems inspections but must restrict their test menu to the enumerated PPM procedures.
A Certificate of Registration is a provisional credential issued while CMS or a deeming organization completes the initial survey of a lab intending to perform nonwaived tests.
A Certificate of Compliance is issued following a direct survey by a CMS-authorized State Survey Agency. It authorizes moderate- or high-complexity testing and requires proficiency testing participation, documented quality control, and biennial inspection.
A Certificate of Accreditation is issued when a lab earns accreditation from a CMS-approved organization (AO) with deeming authority. The College of American Pathologists (CAP), The Joint Commission, COLA, AABB, and A2LA are among the approved AOs. Because deeming AOs must apply standards equal to or more stringent than CLIA requirements, accreditation via an AO signals a higher level of quality system rigor.
| Certificate Type | Authorized Testing | Inspection | Key Regulatory Hook |
|---|---|---|---|
| Certificate of Waiver | Waived tests only | None | Follow manufacturer instructions |
| Certificate for PPM | Enumerated PPM microscopy procedures | None | Limited to PPM test list |
| Certificate of Registration | Nonwaived (provisional) | Pending initial survey | Transitional only |
| Certificate of Compliance | Moderate and high complexity | Biennial, State Survey Agency | 42 CFR Part 493, Subparts H–M |
| Certificate of Accreditation | Moderate and high complexity | Biennial, CMS-approved AO | AO standards must meet or exceed CLIA |
How the FDA Categorizes Test Complexity
Before a laboratory applies for a certificate, the FDA determines where each test system sits in the CLIA complexity framework. For commercially cleared or approved tests, the FDA scores each submission against seven criteria: knowledge required, training, reagent and supply handling, operational steps, calibration and quality control functions, troubleshooting and maintenance, and interpretation and judgment. Each criterion receives a score of 1 to 3; the aggregate determines whether the system is moderate or high complexity. Test systems without an FDA categorization default to high complexity under 42 CFR 493.17.
Waived tests are listed in the CLIA regulations at 42 CFR 493.15(c), cleared for home use, or granted waived status through a CLIA Waiver by Application submission to the FDA. They present minimal risk of an incorrect result and require no formal personnel credentials beyond following manufacturer instructions.
Moderate-complexity tests cover most automated chemistry, hematology, coagulation, and immunoassay analyzers. Complete blood counts, thyroid function tests, and many infectious disease screenings fall here. Labs performing these tests must meet CLIA quality system standards, including proficiency testing, quality control documentation, and Subpart M–qualified personnel.
High-complexity tests carry the most extensive documentation and oversight requirements. This category includes laboratory-developed tests (LDTs), test systems modified from the manufacturer’s cleared instructions, manual differential cell counts, molecular assays such as PCR and next-generation sequencing (NGS), flow cytometry, and histology, pathology, and cytology testing. CLIA requires pre-use method validation covering accuracy, precision, reportable range, analytical sensitivity, and analytical specificity before any LDT reaches patient specimens. See the LDT regulatory overview for the current FDA oversight trajectory.
What Recent CMS Rule Changes Require of Nonwaived Labs
Updated Personnel Qualifications
CMS issued the first comprehensive revision to CLIA laboratory personnel qualifications under Subpart M since 1992. The changes affect all nonwaived laboratories and cover every personnel tier.
Laboratory directors holding an MD or DO degree must also hold board certification in anatomic pathology or clinical pathology from the American Board of Pathology or the American Osteopathic Board of Pathology. The rule formally recognizes the Doctor of Clinical Laboratory Science (DCLS) degree for high-complexity lab director roles, establishes a degree equivalency framework for non-standard credentials, and permanently recognizes U.S. military medical laboratory training programs of at least 50 weeks as a qualifying pathway for high-complexity testing personnel. Degrees in physical science no longer automatically qualify; individuals must demonstrate specific coursework in biology and chemistry. BSN degrees qualify holders as moderate-complexity testing personnel through a separate pathway. A BSN alone does not qualify for high-complexity testing personnel roles; holders must complete additional coursework in laboratory science equivalent to an associate degree in the field. Nursing degrees are excluded entirely from laboratory director and technical consultant positions. Personnel employed in their roles as of the rule’s effective date retain their qualifications as long as they remain continuously employed in those positions.
Proficiency Testing Overhaul
Proficiency testing (PT) is the mechanism by which laboratories compare their results against peer facilities through blind sample challenges graded by approved PT providers. The CMS-3355-F final rule, the first substantive PT update since the original 1992 rules, added 29 new regulated analytes, removed five, revised acceptable performance limits across the existing test menu, and raised the satisfactory performance threshold for unexpected antibody detection from 80% to 100%. It also requires that PT results for microbiology organism identification be reported to the highest taxonomic level at which the lab reports patient results, and extends PT requirements to CLIA-licensed labs not otherwise accredited by an approved AO.
Labs should review prior PT evaluation data against the new acceptable limits, re-examine coefficient of variation (CV%) data, and confirm enrollment for any newly regulated analytes on their test menu. For microbiology and pathogen detection programs specifically, the organism-identification reporting requirement is a material change that affects both documentation and grading.
Quality Control: The Daily Compliance Engine
Under 42 CFR 493.1256, each lab performing nonwaived testing must establish control procedures that monitor the accuracy and precision of the complete analytic process. The lab determines the appropriate number, type, and frequency of QC materials for each test system; specific subspecialty sections of 42 CFR Part 493 Subpart K set out additional requirements, such as two levels of controls for routine chemistry analytes.
Labs must also operate a quality assessment (QA) program linking QC results, PT outcomes, patient complaint logs, personnel training records, and instrument maintenance data. Biennial inspections verify that the QA program is operational, documented, and responsive. CAP and Joint Commission accreditation apply standards that exceed the minimum CLIA floor, which is why buyers often treat AO accreditation as a proxy for overall quality system maturity.
CLIA in High-Complexity and Molecular Workflows
For organizations submitting specimens for genetics and genomic testing or qPCR analysis, partnering with a CLIA-certified high-complexity lab is the regulatory prerequisite for results to be used in patient care decisions. The high-complexity tier also governs biomarker testing programs, where assays for circulating tumor DNA, pharmacogenomic markers, or cardiac troponin variants require validated reference intervals and demonstrated analytical specificity alongside CLIA certification.
For pharmaceutical and biotech clients running pharmacology and drug development studies or clinical trials, the distinction between CLIA-regulated clinical testing and GLP-regulated non-clinical testing is consequential. Clinical biomarker assays supporting regulatory submissions typically require both CLIA certification for the testing lab and assay validation documented to applicable ICH or FDA guidance standards. Aligning these requirements early in study design prevents protocol amendments and data acceptance issues during regulatory review.
Evaluating and Outsourcing to a CLIA-Certified Lab
Organizations outsourcing medical and clinical testing must confirm that their contract lab holds the certificate type appropriate to the tests being ordered. A CoW lab cannot legally perform high-complexity molecular diagnostics on patient specimens. A lab’s CLIA number can be verified through the CMS CLIA program page, which records certificate type, effective date, and specialty authorizations. This step is especially important when testing involves Medicare or Medicaid billing, since CLIA compliance is a condition of reimbursement.
Beyond certificate type, evaluate these CLIA-specific factors:
- PT performance history: Consistent satisfactory scores at the analyte level indicate sustained assay performance, not just one-time certification.
- QC documentation depth: Labs that maintain Levey-Jennings charts, track Westgard rule violations, and document corrective actions demonstrate discipline beyond bare compliance.
- Accreditation scope: Confirm the AO’s deeming authority covers the specialty areas you need; not all AOs are approved for all subspecialties.
- LDT validation records: For novel biomarker or modified assays, including toxicology and biocompatibility testing programs, request the validation package to confirm CLIA performance characteristics have been established for the specific matrix and patient population.
State licensure adds a further layer for multi-state programs. New York and Washington maintain separate, CMS-recognized state laboratory licensing systems that labs must satisfy in addition to, or in lieu of, federal CLIA requirements.
Contract Laboratory connects organizations with CLIA-certified labs across the full complexity spectrum, from routine chemistry panels through high-complexity PCR-based molecular diagnostics. Submitting a lab request surfaces labs whose credentials, specialties, and geographic reach match your specific testing requirements.
Need CLIA-certified laboratory testing? Submit a lab request to connect with and get quotes from industry experts.
This content includes text that has been generated with the assistance of AI. Contract Laboratory encourages the use of new tools and technologies that enhance our editorial process. Our full editorial policy can be found here.
Frequently Asked Questions
Waived tests are simple, low-risk assays that carry minimal chance of an incorrect result if run as directed. Nonwaived tests, comprising moderate- and high-complexity tests, require the lab to be inspected, enroll in proficiency testing, operate documented quality control procedures appropriate to each test system, and employ personnel meeting CLIA Subpart M qualifications.
The FDA scores each commercially cleared or approved test against seven criteria covering knowledge requirements, training, reagent handling, operational steps, QC functions, troubleshooting, and interpretation. Each criterion receives a 1–3 score; the sum determines the complexity category. Uncategorized test systems default to high complexity under 42 CFR 493.17.
CMS issued the first overhaul of Subpart M personnel qualifications since 1992. Key changes include restructured laboratory director requirements linking MD/DO credentials to pathology board certification, recognition of the DCLS degree, and elimination of physical science degrees as automatic qualifiers. The rule also clarifies that a BSN alone does not qualify for high-complexity testing roles without additional laboratory science coursework, and excludes nursing degrees from laboratory director and technical consultant positions.
PT is an external quality assurance mechanism in which enrolled labs receive blind challenge samples and have their results graded against peer performance and defined acceptable limits. The CMS-3355-F final rule added 29 new regulated analytes, removed five, revised acceptable performance limits, raised the unexpected antibody detection threshold to 100% satisfactory performance, and extended PT requirements to labs not accredited by an approved AO.
CMS may grant deeming authority to accreditation organizations whose laboratory standards meet or exceed CLIA requirements. Labs accredited by a deeming organization receive a Certificate of Accreditation in lieu of direct CMS inspection. Approved deeming organizations include CAP, The Joint Commission, COLA, AABB, A2LA, and ACHC.
Yes. LDTs default to high complexity under CLIA. Before any LDT is applied to patient specimens, the lab must document analytical validation establishing accuracy, precision, reportable range, analytical sensitivity, and analytical specificity. The FDA has separately pursued expanded pre-market oversight of LDTs, and the regulatory trajectory for LDTs under FDA authority continues to evolve.